Differentiated Thyroid Carcinoma

Its prognostic value is further amplified by large tumor size, with the coexistence of bilaterality and large tumor diameter identifying a distinct high-risk population, exclusively among BRAF-mutant patients. Incorporating BRAF status into the assessment of patients with bilateral PTC, particularly those with larger tumors, may refine postoperative risk stratification and facilitate more tailored surveillance strategies.

In conclusion, TFHL-associated B/PCP are a heterogeneous group of lymphoproliferative and plasma cell disorders, displaying recurrent histological patterns and frequent clonal hematopoiesis-associated mutations. Further studies on larger cohorts of patients are warranted to elucidate their biological and clinical implications.

The optimal model demonstrated strong discriminative performance and stability across time points, with AUCs (95% confidence intervals) of 0.905 (0.801-1.000), 0.919 (0.857-0.981), and 0.921 (0.861-0.981) at 12, 24, and 36 months, respectively, and showed good calibration. This study demonstrates that integrating treatment response, extrathyroidal/extranodal extension, mitotic count, and Dmut into a predictive nomogram offers a clinically relevant tool for stratifying progression risk in patients with RAI-R PTC.

BRAF-mutant papillary thyroid cancers in the isthmus display distinct molecular characteristics, including increased ERK signaling activity. These findings suggest that topographical location independently influences tumor biology and may account for the more aggressive clinical behavior of isthmus tumors at the molecular level.

Thyroid bed FNA is a reliable method for detecting recurrent thyroid carcinoma, showing 100% cytohistologic concordance for TBS III and above. Tg is not universally elevated in recurrent tumors (sensitivity 57%), but an increased Tg level in the setting of nondiagnostic FNA warrants further evaluation. The 27% rate of unsatisfactory specimens likely reflects postsurgical scarring, which can clinically mimic recurrence.

Genetic analysis of the orbital lesion revealed NRAS, TP53, and CDKN2A mutations. This case highlights the spectrum of uncommon metastases, discordance in molecular imaging, and importance of correlating molecular imaging with molecular pathology.

Furthermore, the effects of the covalent DNMT inhibitor, 5-azacytidine (5-Aza), and the DNMT1-selective inhibitor, GSK-3484862, on cell viability were evaluated in PTC and follicular thyroid carcinoma (FTC) cell lines...Sustained inhibition of DNMT1 effectively reduced global DNA methylation and promoted apoptosis, highlighting the potential of prolonged DNMT1-targeted therapy. Further in vitro and in vivo studies are warranted to validate these results and elucidate the underlying mechanisms.

In vivo, lactylation-deficient CPT1A mutants (K180R/K285R) attenuated lung metastasis and subcutaneous tumor growth in nude mice. This study reveals that lactate-CPT1A axis synergistically amplifies FAO to fuel PTC progression, suggesting CPT1A lactylation as a therapeutic vulnerability for metabolic intervention.

We identified distinct clinical and histologic features, as well as differential PD-Ll expression between cFDCS and EBV + IFDCS, supporting their classification as separate entities. Further molecular studies are needed to investigate their pathogenesis.

Pharmacological inhibition of EZH2 using DS-3201 reproduced some of the molecular effects of viral infection, including increased mutp53 stability...Indeed, the inhibition of SIRT1 with EX-527 reversed mutp53 accumulation but restored c-Myc expression and increased extracellular IL-6 release...These results establish a mechanistic link between viral infection, epigenetic remodeling, and oncogenic dependency. They also suggest that targeting IL-6 signaling could represent a therapeutic vulnerability in HHV-6A-associated thyroid cancer, particularly in combination with SIRT1 inhibitors.

These findings warrant further investigation of hsa-miR-23a-3p and hsa-miR-574-3p in larger cohorts of patients with PTC to validate their potential clinical relevance.